# US 2003/0077249 A1 · Cell activation process and reagents therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077249 A1
- Document ID: US20030077249A1
- Status: Published application
- Kind: A1
- Application number: 09/091,608
- Filed: 1999-05-17
- Published: 2003-04-24
- Earliest claimed: 1999-05-17
- Inventors: CHRISTOPHER ROBERT BEBBINGTON; ALASTAIR DAVID GRIFFITHS LAWSON; ANDREW NEIL, CHARLES WEIR; HELENE MARGARET FINNEY
- Web page: https://patentgrep.com/patent/US20030077249A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A cell activation process is described in which an effector cell is transformed with DNA coding for a chimeric receptor containing two or more different cytoplasmic signalling components. The activated cell may be of use in medicine for example in the treatment of diseases such as cancer

## Claims

### Claim 1

A method of activating a cell as a result of one type of extracellular interaction between said first cell and a molecule associated with a second target cell characterised in that said first cell is provided with a DNA delivery system comprising DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling components, wherein said cytoplasmic components are not naturally linked, and at least one is derived from a membrane spanning polypeptide.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the cytoplasmic signalling components are capable of acting together cooperatively.

### Claim 3 (depends on 1, 2)

A method according to claim 1 or claim 2 wherein said DNA additionally codes for signal peptide, binding and/or transmembrane components of said one or more chimeric receptors, wherein the binding component is capable of recognising a cell surface molecule on a target cell.

### Claim 4 (depends on 3)

A method according to claim 3 wherein the signal peptide, transmembrane and cytoplasmic signalling components and all or part of the binding component are coded for by a single DNA coding sequence.

### Claim 5 (depends on 3)

A method according to claim 3 wherein each cytoplasmic signalling component is coded for by a separate DNA coding sequence, each of DNA sequence additionally coding for a signal peptide, a transmembrane component and all or part of a binding component.

### Claim 6 (depends on 4, 5)

A method according to claim 4 or claim 5 wherein said DNA codes for part of said binding component and an additional separate DNA coding sequence codes for the remainder of the binding component.

### Claim 7 (depends on 5, 6)

A method according to claim 5 or claim 6 wherein the binding component coded for by one DNA sequence is capable of participating in the same type of extracellular binding event as the binding component coded for by any other DNA sequence.

### Claim 8 (depends on 7)

A method according to claim 7 wherein each binding component binds to the same molecule associated with the target cell.

### Claim 9 (depends on 8)

A method according to claim 8 wherein each binding component is the same.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method according to any one of claims 1 to 9 wherein the one or more recombinant chimeric receptors are capable of recognising a viral or cell surface molecule on a target cell.

### Claim 11

A DNA delivery system comprising DNA in association with a carrier said DNA coding for a recombinant chimeric receptor capable of one type of extracellular interaction and comprising two or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide.

### Claim 12

A DNA delivery system comprising DNA in association with a carrier said DNA coding for two or more recombinant chimeric receptors each capable of the same one type of extracellular interaction and wherein each of said receptors comprises one or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide.

### Claim 13 (depends on 11)

A DNA delivery system according to claim 11 wherein said DNA codes in reading frame for:
i) a signal peptide component;
ii) a binding component capable of recognising a cell surface molecule on a target cell;
iii) a transmembrane component,
iv) two or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide; and optionally
v) one or more spacer regions linking any two or more of said i) to iv) components.

### Claim 14 (depends on 11)

A DNA delivery system according to claim 11 wherein said DNA comprises 1) a first DNA which codes in reading frame for:
i) a signal peptide component;
ii) part of a binding component;
iii) a transmembrane component;
iv) two or more cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide; and optionally
v) one or more spacer regions linking any two or more of said i) to iv) components; and 2) a second separate DNA which codes in reading frame for a signal peptide component and a further part of the binding component ii) coded for by said first DNA, such that the binding component parts together are capable of recognising a cell surface molecule on a target cell.

### Claim 15 (depends on 12)

A DNA delivery system according to claim 12 wherein said DNA comprises a first and a second separate DNA each of which codes in reading frame for:
i) a signal peptide component;
ii) a binding component capable of recognising a cell surface molecule on a target cell;
iii) a transmembrane component;
iv) one or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide; and optionally
v) one or more spacer regions linking any two or more of said i) to iv) components; provided that said first DNA codes for at least one signalling component iv) that is not coded for by said second DNA.

### Claim 16 (depends on 12)

A DNA delivery system according to claim 12 wherein said DNA comprises 1) a first and a second separate DNA each of which codes in reading frame for:
i) a signal peptide component;
ii) one part of a binding component;
iii) a transmembrane component;
iv) one or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide; and optionally
v) one or more spacer regions linking any two or more of said i) to iv) components; provided that said first DNA codes for at least one signalling component iv) that is not coded for by said second DNA; and 2) a separate third and fourth DNA each of which codes in reading frame for a signal peptide component and a further part of the binding component ii) coded for by said first and second DNA respectively, such that the binding component parts together provided by the first and third DNA and together provided by the second and fourth DNA are each capable of recognising a cell surface molecule on a target cell.

### Claim 17 (depends on 13, 14, 15, 16)

A DNA delivery system according to claims 13 to 16 wherein each signal peptide component is an immunoglobulin signal sequence.

### Claim 18 (depends on 15, 16, 17)

A DNA delivery system according to claims 15 to 17 wherein the binding component coded for by said first DNA is the same as the binding component coded for by said second DNA.

### Claim 19 (depends on 13, 14, 15, 16, 17, 18)

A DNA delivery system according to claims 13 to 18 wherein the binding component is an antibody or an antigen binding fragment thereof.

### Claim 20 (depends on 19)

A DNA delivery system according to claim 19 wherein the antibody or fragment thereof is an engineered human antibody or antigen binding fragment thereof.

### Claim 21 (depends on 18, 19, 20)

A DNA delivery system according to claims 18 to 20 wherein the binding component is a single chain Fv fragment.

### Claim 22 (depends on 18, 19, 20)

A DNA delivery system according to claims 18 to 20 wherein the binding component is a Fab′ fragment.

### Claim 23 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A DNA delivery system according to any one of claims 13 to 22 wherein the transmembrane component is derived from all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8, CD4, a cytokine receptor or a colony stimulating factor receptor.

### Claim 24 (depends on 23)

A DNA delivery system according to claim 23 wherein the transmembrane component is derived from all or part of CD28.

### Claim 25 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A DNA delivery system according to any one of claims 11 to 24 wherein the cytoplasmic signalling components are capable of acting together cooperatively.

### Claim 26 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A DNA delivery system according to any one of claims 13 to 25 wherein the cytoplasmic signalling components are derived from all or part of the cytoplasmic domains of a zeta, eta or epsilon chain of the T-cell receptor, CD28, the γ chain of a Fc receptor, a cytokine receptor, a colony stimulating factor receptor, a tyrosine kinase or an adhesion molecule, B29, MB-1, CD3 delta, CD3 gamma, CD5 or CD2.

### Claim 27 (depends on 26)

A DNA delivery system according to claim 26 wherein the cytoplasmic signalling components are ITAM containing cytoplasmic components.

### Claim 28 (depends on 26, 27)

A DNA delivery system according to claim 26 or claim 27 wherein the cytoplasmic signalling components are derived from all or part of CD28 and/or the zeta chain of the T-cell receptor.

### Claim 29 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A DNA delivery system according to any one of claims 11 to 28 wherein the cytoplasmic signalling components are in any orientation relative to one another.

### Claim 30 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A DNA delivery system according to any one of claims 13 to 29 wherein said DNA coding for components i) to iv) additionally codes for one or more spacer regions linking the binding component ii) and the transmembrane component iii).

### Claim 31 (depends on 30)

A DNA delivery system according to claim 30 wherein two or more different spacer regions link the binding component ii) and the transmembrane component iii), both regions either being coded for by one DNA sequence or when a first and second DNA sequence is present one region being coded for by said first DNA and the other different region being coded for by said second DNA.

### Claim 32 (depends on 30, 31)

A DNA delivery system according to claims 30 or claim 31 wherein the spacer region is selected to provide one or more free thiol groups.

### Claim 33 (depends on 30, 31, 32)

A DNA delivery system according to claims 30 to 32 wherein the spacer region is derived from all or part of the extracellular region of CD8, CD4 or CD28.

### Claim 34 (depends on 30, 32)

A DNA delivery system according to claims 30 or claim 32 wherein the spacer region is all or part of an antibody constant region.

### Claim 35 (depends on 30, 31, 32)

A DNA delivery system according to claims 30 to 32 wherein the spacer region is derived from all or part of an antibody hinge region linked to all or part of the extracellular region of CD28.

### Claim 36 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

A DNA delivery system according to any one of claims 11 to 35 wherein the carrier is a viral vector or a non-viral vector.

### Claim 37 (depends on 36)

A DNA delivery system according to claim 36 wherein the non-viral vector is a liposomal vector.

### Claim 38 (depends on 37)

A DNA delivery system according to claim 37 wherein the carrier is a targeted non-viral vector.

### Claim 39 (depends on 38)

A DNA delivery system according to claim 38 wherein the targeted vector is an antibody targeted liposome.

### Claim 40 (depends on 38)

A DNA delivery system according to claim 38 wherein the targeted vector is an antibody targeted condensed DNA.

### Claim 41 (depends on 40)

A DNA delivery system according to claim 40 wherein the targeted vector is an antibody targeted protamine or polylysine condensed DNA.

### Claim 42 (depends on 38)

A DNA delivery system according to claim 38 wherein the targeted vector is antibody targeted naked DNA.

### Claim 43 (depends on 39, 40, 41, 42)

A DNA delivery system according to claims 39 to 42 wherein the antibody is a whole antibody or an antigen binding fragment thereof.

### Claim 44 (depends on 43)

A DNA delivery system according to claim 43 wherein the antibody is an engineered human antibody or an antigen binding fragment thereof.

### Claim 45 (depends on 1, 444)

An effector cell transfected with a DNA delivery system according to any one of claims 1 to 444.

### Claim 46 (depends on 45)

An effector cell according to claim 45 which is a lymphocyte, a dendritic cell, a B-cell, a haematopoietic stem cell, a macrophage, a monocyte or a NK cell.

### Claim 47 (depends on 46)

An effector cell according to claim 46 which is a cytotoxic T-lymphocyte.

### Claim 48 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A DNA delivery system according to any one of claims 11 to 47 for use in the treatment of infectious disease, inflammatory disease. cancer, allergic/atopic disease, congenital disease, dermatologic disease, neurologic disease, transplants and metabolic/idiopathic disease.

### Claim 49 (depends on 48)

A DNA delivery system according to claim 48 for use in the treatment of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, eczema, cystic fibrosis, sickle cell anaemia, psoriasis, multiple sclerosis, organ or tissue transplant rejection, graft-versus-host disease or diabetes.

### Claim 50 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A pharmaceutical composition comprising a DNA delivery system according to any one of claims 11 to 44 together with one or more formulatory agents.

### Claim 51 (depends on 50)

A pharmaceutical composition according to claim 50 wherein the formulatory agent is a suspending, preservative, stabilising and/or dispersing agent.

### Claim 52 (depends on 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

DNA coding for a recombinant chimeric receptor for use in a delivery system according to any one of claims 11 to 44.
